National and Kapodistrian University of Athens
Βιολογικοί παράγοντες και κλινικά χαρακτηριστικά κατά τη διάγνωση και υποτροπή του λεμφώματος Hodgkin: συσχετίσεις και προγνωστική σημασία
Abstract
dc:descriptionDespite high cure rates first line treatment fails in 5-10% of patients with early and 25-30% of patients with advanced stage Hodgkin’s lymphoma. Conversely many early stage patients as well as 1/3 of advanced stage patients are overtreated with 6-8 cycles of ABVD with or without radiotherapy. The ability of conventional clinical and laboratory prognostic factors to correctly identify these patient subgroups is limited. Recent progress in the field of the biology of Hodgkin’s lymphoma has resulted to the evaluation of several biological markers as potential prognostic factors for Hodgkin’s lymphoma. Biological markers may be more potent predictors of the outcome than conventional prognostic factors, correlate directly with the biology of the disease, and may guide the rational design of experimental treatment approaches. In the present study we evaluated the prognostic implication of conventional and several biological markers in a large series of 697 patients with Hodgkin’s lymphoma, treated with ABVD or equivalent regimens with or without radiotherapy. In clinical stages IA/IIA independent prognostic factors were age > 45 years, male gender, extranodal extension, leukocytosis > 10x109/l and the presence of bulky disease, defined as bulky mediastinal mass (>0.33) and/or peripheral or abdominal mass > 7 cm. The resulting prognostic model was more effective than the classifications of the GHSG and the EORTC. In clinical stages IB, IIB, III and IV the number of involved anatomic sites and the value of the International Prognostic Score (IPS) provided independent prognostic information. Patients with > 5 involved sites and IPS > 3 (22% of the total population) had a > 50% 10-year probability of failure, forming a relatively sizeable target group, which may be suitable for experimental therapy. AmongΔιδακτορική Διατριβή Ιατρού Θ.Π. Βασιλακόπουλου 228biological prognostic factors ß2-microglobulin independently affected the prognosis of early stage patients. In contrast serum interleukin-10 and soluble CD30 levels were independent prognostic factors for advanced disease. The combination of elevated serum interleukin-10 levels, elevated serum soluble CD30 levels and stage IV discriminated two groups of patients with excellent and poor prognosis. Therefore this prognostic approach deserves further investigation. We did not identify any correlation between bcl-2 or LMP-1 expression and prognosis. Serum levels of syndecan-1 were elevated in patients with Hodgkin’s lymphoma but did not correlate with prognosis. Serum levels of metalloproteinase-9 were marginally elevated in patients with Hodgkin’s lymphoma, with higher levels correlating with better outcome. Prognostic determinants of the outcome of relapsing disease were the short interval between the end of primary treatment and the documentation ofrelapse (< 6 months), the presence of extranodal involvement or anemia at relapse and the involvement of > 5 anatomic sites at diagnosis. Serum interleukin-10 at relapse was the only significant biological prognostic factor. Cooperative groups are currently evaluating prognostic systems including both conventional and biological prognostic factors. The above named as well as other biological markers should be incorporated as baseline information in prospective clinical trials, in order to estimate their precise prognostic role.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2004
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Vassilakopoulos, Theodoros
- Βασιλακόπουλος, Θεόδωρος
Subjects
dc:subject × 19- Λέμφωμα Hodgkin
- Προγνωστικοί παράγοντες
- β2 - μικροσφαιρίνη
- Ιντερλευκίνη-10
- Διαλυτό CD30
- Μεταλλοπρωτεϊνάση-9
- Hodgkin's lymphoma
- Prognostic factors
- B2-Microglobulin
- Interleukin-10
- Soluble CD30
- Bcl-2
- LMP-1
- Serum metalloproteinases (MMPs)
- Serum SYNDECAN-1
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Medical and Health Sciences
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/23377